Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-alpha therapy during pregnancy: three-center study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10193779" target="_blank" >RIV/00216208:11110/13:10193779 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/13:10193779

Výsledek na webu

<a href="http://dx.doi.org/10.3109/00365521.2013.812141" target="_blank" >http://dx.doi.org/10.3109/00365521.2013.812141</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3109/00365521.2013.812141" target="_blank" >10.3109/00365521.2013.812141</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-alpha therapy during pregnancy: three-center study

Popis výsledku v původním jazyce

Objective. Substantial number of women with inflammatory bowel disease (IBD) conceives while on anti-TNF-alpha therapy. The aim was to assess the safety and efficacy of anti-TNF-alpha treatment during pregnancy and to analyze relationship of neonatal andmaternal anti-TNF-alpha levels at delivery with gestational age at the last exposure. Material and methods. Women with IBD exposed to anti-TNF-alpha therapy during pregnancy were included. Data on anti-TNF-alpha treatment, disease activity, concomitantmedication, pregnancy and newborn outcome were recorded. Anti-TNF-alpha levels from cord blood were assessed by ELISA. Results. Forty-one pregnancies (27 Crohn's disease; 14 ulcerative colitis) were exposed to infliximab (IFX; 32) and adalimumab (ADA; 9). Ten (24%) women had active disease at conception and 31 (76%) were in remission with 3 patients experiencing relapse during pregnancy. Anti-TNF-alpha therapy started prior to and after conception in 32 and 9 women, respectively. There w

Název v anglickém jazyce

Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-alpha therapy during pregnancy: three-center study

Popis výsledku anglicky

Objective. Substantial number of women with inflammatory bowel disease (IBD) conceives while on anti-TNF-alpha therapy. The aim was to assess the safety and efficacy of anti-TNF-alpha treatment during pregnancy and to analyze relationship of neonatal andmaternal anti-TNF-alpha levels at delivery with gestational age at the last exposure. Material and methods. Women with IBD exposed to anti-TNF-alpha therapy during pregnancy were included. Data on anti-TNF-alpha treatment, disease activity, concomitantmedication, pregnancy and newborn outcome were recorded. Anti-TNF-alpha levels from cord blood were assessed by ELISA. Results. Forty-one pregnancies (27 Crohn's disease; 14 ulcerative colitis) were exposed to infliximab (IFX; 32) and adalimumab (ADA; 9). Ten (24%) women had active disease at conception and 31 (76%) were in remission with 3 patients experiencing relapse during pregnancy. Anti-TNF-alpha therapy started prior to and after conception in 32 and 9 women, respectively. There w

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EC - Imunologie

OECD FORD obor

—

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Scandinavian Journal of Gastroenterology

ISSN

0036-5521

e-ISSN

—

Svazek periodika

48

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

951-958

Kód UT WoS článku

000322850500008

EID výsledku v databázi Scopus

—